GFAP and NfL in Clinical Practice

GFAP is a structural protein expressed in astrocytes. When astrocytes are damaged, GFAP enters the bloodstream in measurable quantities. Levels rise within hours of injury, peak within roughly 20–24 hours, and then decline over several days.

Because of that kinetic profile, GFAP is best suited to acute evaluation — emergency department triage, decisions about repeat imaging, and confirmation that a biological injury occurred.

NfL is a cytoskeletal protein found in axons. Its half-life in blood is long — weeks rather than hours — which makes it valuable for tracking ongoing axonal injury and neurodegeneration.

Elevated NfL months after an event is a meaningful signal of persistent injury. Serial measurements over time can document trajectory: healing, plateau, or progression.

For GFAP, draw within 24 hours of injury for maximum sensitivity. The FDA-cleared indication uses a window of up to 12 hours; research-grade assays extend usefulness to 48 hours or longer.

For NfL, timing is more forgiving. Draws from days to months post-injury remain interpretable, especially in the context of a known baseline or serial measurements.

Biomarker results are quantitative. Thresholds vary by assay platform and by reference population, but the common pattern is: a low value rules out clinically significant injury with high negative predictive value; an elevated value confirms a biological event and prompts further evaluation.

Interpretation is most useful when paired with clinical context — mechanism, symptoms, exam findings, and imaging — rather than as a standalone number.

For recovery monitoring, a three-point protocol is practical: acute (within the diagnostic window), subacute (2–4 weeks), and follow-up (3–6 months). The trajectory across those points is often more informative than any single value.

In athletic and military settings, a pre-exposure baseline draw enables individualized comparisons rather than reliance on population norms.

Biomarker results should support, not replace, clinical judgment. A positive marker with persistent symptoms argues for active management: imaging, specialist referral, work or play restriction. A negative marker in a symptomatic patient directs evaluation toward non-injury causes.

The goal is not to replace neurological examination but to add an objective layer that has, until recently, been unavailable in TBI care.